a public good project by the
Synthesis
Company
of California

© 2026

Rachel C. Jankowitz | doi.page

0 works0 citations0 h-index

Rachel C. Jankowitz

Magee-Womens Research Institute(US)Magee-Womens Hospital(US)Cancer Research Center(US)UPMC Hillman Cancer Center(US)University of Pennsylvania(US)

Publications by Year

Research Areas

Breast Cancer Treatment Studies, HER2/EGFR in Cancer Research, Epigenetics and DNA Methylation, Histone Deacetylase Inhibitors Research, Advanced Breast Cancer Therapies

Most-Cited Works

→ Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology(2022)945 cited
→ Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology(2024)459 cited
→ NCCN Guidelines® Insights: Breast Cancer, Version 4.2023(2023)415 cited
→ NCCN Guidelines® Insights: Breast Cancer, Version 4.2021(2021)348 cited
→ TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases(2019)336 cited
→ A deep learning method for classifying mammographic breast density categories(2017)262 cited

→ Breast Cancer Index Identifies Early-Stage Estrogen Receptor–Positive Breast Cancer Patients at Risk for Early- and Late-Distant Recurrence(2013)

224 cited

→ Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis(2013)191 cited

→ Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study(2016)158 cited

→ Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial(2021)132 cited